These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 24687233

  • 1. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D.
    BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L, Lapadula G, Mathieu A.
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [Abstract] [Full Text] [Related]

  • 3. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G.
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL, Valesini G.
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [Abstract] [Full Text] [Related]

  • 5. [Certolizumab pegol].
    Delgado Frías E, Díaz González JF.
    Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
    [Abstract] [Full Text] [Related]

  • 6. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage.
    Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379
    [Abstract] [Full Text] [Related]

  • 7. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U.
    Swiss Med Wkly; 2014 Dec; 144():w13950. PubMed ID: 24723273
    [Abstract] [Full Text] [Related]

  • 8. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs.
    Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, Nagasawa H, Seto Y, Koike T, Miyasaka N.
    Mod Rheumatol; 2013 Mar; 23(2):284-96. PubMed ID: 22588312
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 10. Drug safety evaluation of certolizumab pegol.
    Ferrante M, Vermeire S, Rutgeerts PJ.
    Expert Opin Drug Saf; 2014 Feb; 13(2):255-66. PubMed ID: 24156537
    [Abstract] [Full Text] [Related]

  • 11. Certolizumab pegol in rheumatoid arthritis: current update.
    Fechtenbaum M, Md Yusof MY, Emery P.
    Expert Opin Biol Ther; 2014 Jun; 14(6):841-50. PubMed ID: 24654999
    [Abstract] [Full Text] [Related]

  • 12. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 14. Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
    Patel AM, Moreland LW.
    Expert Rev Clin Immunol; 2010 Nov 10; 6(6):855-66. PubMed ID: 20979550
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 10; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 16. Biologic agents in rheumatology: act II.
    Kavanaugh A.
    Clin Exp Rheumatol; 2010 Sep 10; 28(3 Suppl 59):S2-4. PubMed ID: 20576218
    [No Abstract] [Full Text] [Related]

  • 17. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB, Kniazev OV.
    Eksp Klin Gastroenterol; 2012 Sep 10; (3):100-5. PubMed ID: 22830233
    [No Abstract] [Full Text] [Related]

  • 18. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb 03; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract] [Full Text] [Related]

  • 19. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F, Niccoli L, Goletti D.
    J Rheumatol Suppl; 2014 May 03; 91():56-64. PubMed ID: 24789001
    [Abstract] [Full Text] [Related]

  • 20. Interstitial lung disease following certolizumab pegol.
    Pearce F, Johnson SR, Courtney P.
    Rheumatology (Oxford); 2012 Mar 03; 51(3):578-80. PubMed ID: 22116998
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.